Research

Cellular

Treatment-limiting gastrointestinal side effects occurred in 16.7% of patients.

Clinicians should monitor for gastrointestinal side effects in patients taking semaglutide.

StrongSupportsmedium confidence
Treatment-limiting gastrointestinal side effects occurred in 16.7% of patients.
Francis G. Wade et al. · Clinical Transplantation · 2025

Why this rating

Based on a retrospective chart review of 36 patients.

Source

Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation

Francis G. Wade et al. · Clinical Transplantation · 2025

DOI 10.1111/ctr.70344

cohort · n=36Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →